News | News By Subject | News by Disease News By Date | Search News

Restless legs (Akathisia) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
GlaxoSmithKline (GSK)'s Contract Manufacturing Delays Cause Shortage of Restless Leg Treatment     4/18/2013
UCB, Inc. (UCBJF.PK)'s Neupro® Approved by FDA for Parkinson's Disease and Restless Legs Syndrome     4/4/2012
Pfizer Inc. (PFE)'s Lyrica Helps in Phase III Restless Legs Syndrome Study     12/16/2011
U.S. Denies Approval of XenoPort, Inc. (XNPT), GlaxoSmithKline (GSK) RLS Drug; Xenoport     2/18/2010
XenoPort, Inc. (XNPT) Announces Extension of the Horizant PDUFA Date to February 11, 2010     2/10/2010
Health Canada Approves Centocor Ortho Biotech Inc. and Schering-Plough Corporation (SGP)'s SIMPONI(TM) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis; First World Regulatory Approval for SIMPONI     4/14/2009
XenoPort, Inc. (XNPT) to Receive $23 Million in Milestone Payments Associated With FDA Acceptance of Solzira NDA     3/16/2009
UCB Group (UCBJF.PK) Receives U.S. FDA Complete Response Letter for Neupro(R) in Restless Legs Syndrome and Advanced Parkinson's Disease     12/19/2008
Neurogen Corporation (NRGN) Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson's Disease     10/14/2008
XenoPort, Inc. (XNPT), GlaxoSmithKline (GSK) Restless Legs Drug Meets Main Goals in Trial     2/28/2008
GlaxoSmithKline (GSK) (Jobs) Says FDA has Questions on Restless Legs Drug     8/13/2007
GlaxoSmithKline (GSK) (Jobs) And XenoPort, Inc. (XNPT) (Jobs) Announce Agreement On Late-Stage Compound For RLS And Neuropathic Pain; XenoPort To Receive Upfront $75M     2/8/2007
Neurogen (NRGN) In-licenses Drug Candidate For Parkinson's Disease And Restless Legs Syndrome From Wyeth (WYE)     11/28/2006

News from Around the Web
Men With Restless Legs May Die Early, Brigham and Women's Hospital Study     6/13/2013
Restless Legs Syndrome Linked to Erectile Dysfunction, Harvard University Study     6/16/2011
Parkinson's Drug Could Treat Restless Leg Syndrome, Medical College of Georgia Study     12/7/2010
Belly Fat May Raise Restless Legs Risk, Harvard School of Public Health Study     4/7/2009
Spinal Anesthesia Doesn't Cause Restless Leg Syndrome, University of Gottingen Medical School Study     11/20/2008
Drugs for Restless Legs Syndrome Have Downsides, University of Connecticut Study     5/13/2008
Restless Legs Syndrome Doubles Risk of Stroke and Heart Disease     1/2/2008
Gambling And Increased Sexual Desire Linked To Restless Leg Syndrome     10/31/2007
Emory University Studies Find Gene Linked to Night Leg Movement     7/19/2007
Pharma Companies Creating Diseases To Sell Their Medicines     4/11/2006
Restless Legs Syndrome Linked To Psychiatric Conditions     10/31/2005
Restless Leg Syndrome Runs In Families, Study Says     4/12/2005
Low Iron Linked To Restless Legs     12/30/2004
Genes To Blame For Restless Sleep     11/24/2004
Pregnancy Ups Risk Of Restless Leg Syndrome     9/28/2004

Press Releases
Sensory NeuroStimulation Release: Relaxis Pad For Restless Legs Syndrome Helps Patients Avoid General Anesthesia     10/4/2016
XenoPort (XNPT) Release: #StopMakingExcuses Awareness Campaign for Restless Legs Syndrome Launches During Sleep Awareness Week 2016     3/7/2016
Sensory Neurostimulation Announces Issuance Of U.S. Patent For Relaxis™, The First And Only FDA -Cleared Non-Drug Treatment To Improve Sleep For Patients With Restless Legs Syndrome     4/30/2015
Mundipharma AG Receives Positive European Commission Decision On Targin® (Oxycodone/Naloxone) For The Treatment Of Restless Legs Syndrome     1/7/2015
Mundipharma AG Receives Positive CHMP Opinion For Targin® (Oxycodone / Naloxone) For The Treatment Of Restless Legs Syndrome1     10/24/2014
XenoPort, Inc. (XNPT) Release: RLS/WED Survey Of Patients’ Spouses And Partners Reveals Their Concern Of Disease-Related Burdens     2/13/2014
XenoPort, Inc. (XNPT) Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines for Long-Term Treatment of Restless Legs Syndrome/Willis-Ekbom Disease     7/23/2013
UCB, Inc. (UCBJF.PK) Launches Neupro® in the U.S. to Treat Parkinson's Disease and Restless Legs Syndrome     7/16/2012
Astellas Pharma Inc. (YPH.BE) and XenoPort, Inc. (XNPT) Announce the Launch of Regnite® Tablets for Restless Legs Syndrome in Japan     7/9/2012
UCB Group (UCBJF.PK) Release: First Assessment of Individual RLS Domains in New Post-Hoc Analyses of Neupro® Studies     4/25/2012
Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome     12/19/2011
UCB, Inc. (UCBJF.PK) Release: New Post Hoc Analyses Examined the Effects of Neupro® (Rotigotine Transdermal System) on Daytime Functioning, Daytime Symptoms, Pain and Mood in Restless Legs Syndrome     6/10/2011
Impax Pharmaceuticals Provides an Update on Pipeline Candidate IPX159     5/10/2011
UCB, Inc. (UCBJF.PK): Study Showed the Clinically Significant Therapeutic Benefit of Neupro(R) (rotigotine transdermal system) in the Treatment of Restless Legs Syndrome     7/28/2010
FDA Asks for More Preclinical Data on XenoPort, Inc. (XNPT) RLS Drug     5/26/2010